<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Llewellyn-Bennett R</submitter><funding>National Centre for the Replacement, Refinement and Reduction of Animals in Research</funding><funding>Medical Research Council</funding><funding>Alzheimers Research UK</funding><funding>National Institute for Health Research (NIHR)</funding><funding>Alzheimer's Society</funding><funding>Royal College of Surgeons of England</funding><pagination>298</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5975470</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>19(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Randomised controlled clinical trials typically have a relatively brief in-trial follow-up period which can underestimate safety signals and fail to detect long-term hazards, which may take years to appear. Extended follow-up after the scheduled closure of the trial allows detection of both persistent or enhanced beneficial effects following cessation of study treatment (i.e. a legacy effect) and the emergence of possible adverse effects (e.g. development of cancer).&lt;h4>Methods&lt;/h4>A systematic review was conducted following PRISMA guidelines to qualitatively compare post-trial follow-up methods used in large randomised controlled trials. Five bibliographic databases, including Medline and the Cochrane Library, and one trial registry were searched. All large randomised c</pubmed_abstract><journal>Trials</journal><pubmed_title>Post-trial follow-up methodology in large randomised controlled trials: a systematic review.</pubmed_title><pmcid>PMC5975470</pmcid><funding_grant_id>MC_U137686861</funding_grant_id><funding_grant_id>MR/L023784/2</funding_grant_id><funding_grant_id>CL-2015-16-001</funding_grant_id><funding_grant_id>HDR-4002</funding_grant_id><funding_grant_id>Research Fellowship</funding_grant_id><funding_grant_id>ART-PPG2005A-2</funding_grant_id><funding_grant_id>151</funding_grant_id><funding_grant_id>G0800701/1</funding_grant_id><funding_grant_id>ARUK-PPG2014A-8</funding_grant_id><pubmed_authors>Hainsworth AH</pubmed_authors><pubmed_authors>Bowman L</pubmed_authors><pubmed_authors>Edwards D</pubmed_authors><pubmed_authors>Roberts N</pubmed_authors><pubmed_authors>Llewellyn-Bennett R</pubmed_authors><pubmed_authors>Bulbulia R</pubmed_authors></additional><is_claimable>false</is_claimable><name>Post-trial follow-up methodology in large randomised controlled trials: a systematic review.</name><description>&lt;h4>Background&lt;/h4>Randomised controlled clinical trials typically have a relatively brief in-trial follow-up period which can underestimate safety signals and fail to detect long-term hazards, which may take years to appear. Extended follow-up after the scheduled closure of the trial allows detection of both persistent or enhanced beneficial effects following cessation of study treatment (i.e. a legacy effect) and the emergence of possible adverse effects (e.g. development of cancer).&lt;h4>Methods&lt;/h4>A systematic review was conducted following PRISMA guidelines to qualitatively compare post-trial follow-up methods used in large randomised controlled trials. Five bibliographic databases, including Medline and the Cochrane Library, and one trial registry were searched. All large randomised c</description><dates><release>2018-01-01T00:00:00Z</release><publication>2018 May</publication><modification>2025-04-18T17:31:43.136Z</modification><creation>2019-03-26T23:39:39Z</creation></dates><accession>S-EPMC5975470</accession><cross_references><pubmed>29843774</pubmed><doi>10.1186/s13063-018-2653-0</doi></cross_references></HashMap>